Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Olmesartan (formerly also known as CS-866) is a potent and selective angiotensin II type 1 (AT(1)) receptor antagonist used in the treatment of high blood pressure. It also prevents renin secretion from receiving a negative regulatory feedback. Vasodilation and a decrease in peripheral resistance occur as a result of receptor suppression. Lipid hydroxyproline content and TGF-beta1 are markedly decreased by olmesartan medoxomil.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Enzyme Assay |
Olmesartan medoxomil, with an IC50 of 66.2 μM, is a strong and specific inhibitor of the angiotensin AT1 receptor.
|
||
Cell Assay |
Cell Line: Human cervical cancer cell line (HeLa)
Concentration: 0.7- 5 mM Incubation Time: 24, 48 and 72 h Result: IC50s against HeLa cell line are 4.685 and 1.651 mM for 48 and 72 h, respectively |
||
Animal Protocol |
|
||
References |
|
Molecular Formula |
C24H26N6O3
|
|
---|---|---|
Molecular Weight |
446.50
|
|
Exact Mass |
446.21
|
|
Elemental Analysis |
C, 64.56; H, 5.87; N, 18.82; O, 10.75
|
|
CAS # |
144689-24-7
|
|
Related CAS # |
Olmesartan-d4; 1420880-41-6; Olmesartan-d6; 1185144-74-4; Olmesartan medoxomil; 144689-63-4
|
|
Appearance |
Solid powder
|
|
SMILES |
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O
|
|
InChi Key |
VTRAEEWXHOVJFV-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
|
|
Chemical Name |
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL | |
5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL | |
10 mM | 0.2240 mL | 1.1198 mL | 2.2396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05103332 | Active Recruiting |
Drug: Olmesartan Drug: Amlodipine |
Hypertension | Alnylam Pharmaceuticals | November 5, 2021 | Phase 2 |
NCT05411887 | Recruiting | Drug: Rosuvastatin, Olmesartan Medoxomil |
Hyperlipidemias Hypertension |
Daewoong Pharmaceutical Co. LTD. | June 20, 2022 | N/A |
NCT02483936 | Not yet recruiting | Drug: Olmesartan medoxomil 40mg + chlorthalidone 12,5mg Drug: Olmesartan 40mg + Hydrochlorothiazide 25mg |
Arterial Hypertension | EMS | April 2023 | Phase 3 |
NCT02493322 | Not yet recruiting | Drug: Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg Drug: Olmesartan medoxomil 20mg + Chlortalidone 25mg |
Essential Arterial Hypertension | EMS | April 2023 | Phase 3 |
NCT05917275 | Not yet recruiting | Drug: Amlodipine Drug: Olmesartan |
Primary Hypertension | Radboud University Medical Center |
October 2023 | Phase 4 |
Effects of telmisartan (Tel) (A) and olmesartan (Olm) (B) after dosing for more than 4 weeks on mean arterial blood pressure (MAP) in SHR fed a high fat diet (HFD). J Pharmacol Sci . 2016 Jul;131(3):190-7. td> |
Effects of telmisartan (HFD-Tel) and olmesartan (HFD-Olm) for 10 weeks on body weight (BW) change (A), food intake (B) and blood pressure (BP) (C) in SHR fed a high fat diet (HFD). J Pharmacol Sci . 2016 Jul;131(3):190-7. td> |
Effects of telmisartan (HFD-Tel) and olmesartan (HFD-Olm) for 9 weeks on insulin tolerance test (ITT) (A) and for 11 weeks on serum adiponectin concentration (B) in SHR fed a high fat diet (HFD). J Pharmacol Sci . 2016 Jul;131(3):190-7. td> |